KCM
TSHA icon

Kynam Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Kynam Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,281,313
Closed -$10.4M – 33
2023
Q3 		$10.4M Buy
+3,281,313
New +$6.13M 1.7% 15

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Kynam Capital Management's TSHA Position: Q4 2023 in Review

Kynam Capital Management sold out of Taysha Gene Therapies (TSHA) in Q4 2023, closing a stake of 3,281,313 shares — an estimated $10.4M sold.

Kynam Capital Management first reported a position in TSHA in Q3 2023 and held it in 1 quarter. The position peaked at $10.4M in Q3 2023. 87 funds tracked by Wall St. Rank hold TSHA as of Q4 2023.

  • Kynam Capital Management reported no remaining Taysha Gene Therapies position as of Q4 2023 after selling out during the quarter.
  • Kynam Capital Management sold 3,281,313 Taysha Gene Therapies shares in Q4 2023, an estimated $10.4M.
  • Kynam Capital Management first reported a position in Taysha Gene Therapies in Q3 2023 and held it in 1 quarter.
  • Kynam Capital Management's Taysha Gene Therapies position peaked at $10.4M in Q3 2023.
  • 87 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2023.

Based on Kynam Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.